Peranan Kortikosteroid Terhadap Luaran Pasien COVID-19
Sebuah Tinjauan Literatur
DOI:
https://doi.org/10.55606/detector.v2i3.4008Keywords:
COVID-19, Corticosteroid, MedicineAbstract
Corticosteroid is one of the COVID-19 drug agents that has a pros and cons of its use because there has been a research that shows this drug had a negative impact and also there has been a research that recommend its use.This literature study conducted to discuss about role of corticosteroid towards COVID-19 patient’s outcome. This paper is a literature review that evaluates variant journals of original research with clinical study design about role of corticosteroid towards COVID-19 patient's outcome by selecting through electronic database such as PubMed, ScienceDirect, and CENTRAL with designated keywords. There are 16 literatures of clinical study design found through PubMed, ScienceDirect, and CENTRAL. It is know that the role of corticosteroid depend on patient's clinical characteristic and time given to the patients. It can be concluded that corticosteroid had role on improving oxygenation on patients with moderate-critical symptoms, reducing mortality rate on critical patients with hyperinflammation, and reducing the lenght of stay in the hospital.
Downloads
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ [Internet]. 2020;371. Available from: https://www.bmj.com/content/371/bmj.m3862
Miller S. General Properties of Viruses. In: Carrol KC, Hobden JC, Miller S, Morse SA, Mietzner TA, Detrick B, editors. Jawetz, Melnick & Adelberg's medical microbiology. 27th ed. New York : Mcgraw-Hill Education;2015. p.397–419.
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–18.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J [Internet]. 2020 Apr 1;55(4):2000607. Available from: http://erj.ersjournals.com/content/55/4/2000607.abstract
Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020 May;55(5):105951.
Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis. 2005;24:583–91.
Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023.
Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. Can Med Assoc J [Internet]. 2020 Jul 6;192(27):E756 LP-E767. Available from: http://www.cmaj.ca/content/192/27/E756.abstract
Patel VK, Shirbhate E, Patel P, Veerasamy R, Sharma PC, Rajak H. Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. Beni-Suef Univ J Basic Appl Sci [Internet]. 2021 Dec 1 [cited 2022 Mar 10];10(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567120/
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;324(13):1307–16.
Monedero P, Gea A, Castro P, Candela-Toha AM, Hernández-Sanz ML, Arruti E, et al. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Crit Care [Internet]. 2021;25(1):1–13. Available from: https://doi.org/10.1186/s13054-020-03422-3
Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr. 2021;133(7–8):303–11.
Vidal-Cortés P, Río-Carbajo L Del, Olmo JN Del, Prol-Silva E, Tizón-Varela AI, Rodríguez-Vázquez A, et al. Covid-19 and acute respiratory distress syndrome. Impact of corticosteroid treatment and predictors of poor outcome. Rev Esp Quimioter. 2021;34(1):33–43.
Aggarwal A, Mittal A, Soneja M, Shankar SH, Naik S, Kodan P, et al. Role of systemic corticosteroids in preventing hypoxia among patients with mild COVID-19: An observational study. Drug Discov Ther. 2021;15(5):273–7.
Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Rodríguez Gullello EA, Collado Pérez I, et al. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. Med Clínica.2021;156(1):7–12.
Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect [Internet]. 2021 Jan 1 [cited 2022 Mar 21];27(1):105–11. Available from: https://doi.org/10.1016/j.cmi.2020.09.0141198-743X/
Wu C, Hou D, Du C, Cai Y, Zheng J, Xu J, et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. Crit Care [Internet]. 2020;24(1):1–10. Available from: https://doi.org/10.1186/s13054-020-03340-4
Bahl A, Johnson S, Chen NW. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern Emerg Med [Internet]. 2021;16(6):1593–603. Available from: https://doi.org/10.1007/s11739-021-02655-6
Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res [Internet]. 2021;22(1):1–14. Available from: https://doi.org/10.1186/s12931-021-01833-6
Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020 May;212(9):416–20.
Chen H, Xie J, Su N, Wang J, Sun Q, Li S, et al. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. Chest [Internet]. 2021;159(5):1793–802. Available from: https://doi.org/10.1016/j.chest.2020.11.050
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial (BMC Infectious Diseases, (2021), 21, 1, (337), 10.1186/s12879-021-06. BMC Infect Dis. 2021;21(1):1–8.
Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T, Wahlin RR, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive without Life Support in Adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA - J Am Med Assoc. 2021;326(18):1807–17.
Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16:1–13.
Granholm A, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med [Internet]. 2022;48(1):45–55. Available from: https://doi.org/10.1007/s00134-021-06573-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Detector: Jurnal Inovasi Riset Ilmu Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
